Physician profile
Mark W Mittauer
NPI 1255322996
$22,988.28
in general payments reported to CMS, 2019-2025
28 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,842 · 2020: $2,266 · 2021: $9,101 · 2022: $2,802 · 2023: $901 · 2024: $1,058 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,977.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,773.34 | 2021-2025 | |
| Allergan, INC. | $4,868.16 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $3,044.43 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $900.81 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $885.16 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $799.75 | 2020-2025 | Caplyta |
| Alkermes, INC. | $696.87 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $669.28 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $469.40 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $356.05 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $274.51 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $271.43 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $190.08 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $147.84 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $105.82 | 2025 | Fanapt |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $78.40 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $75.78 | 2023-2025 | Auvelity |
| Shire North American Group INC | $65.79 | 2019 | |
| Harmony Biosciences LLC | $61.96 | 2023-2025 | Wakix |
| Viewray Technologies INC | $53.80 | 2022 | |
| Collegium Pharmaceutical, INC. | $45.07 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $43.78 | 2023-2024 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $31.52 | 2025 | Cobenfy |
| Adlon Therapeutics L.P. | $18.36 | 2021 | |
| Merck Sharp & Dohme LLC | $17.61 | 2020 | |
| Bausch Health US, LLC | $14.92 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.71 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $13.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mittauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.